On Apr. 17, 2020, after promising COVID-19 treatments in Germany, France, Italy, Spain and the U.S,, ExThera Medical’s Seraph-100 Microbind Affinity Blood Filter (Seraph 100) has been granted Emergency Use Authorization by the U.S. Food and Drug Administration (FDA). This approval comes soon after first use of the device to treat COVID-19 patients in Europe and in U.S. and will facilitate Seraph 100 use in U.S. hospitals.

It appeared that Seraph 100 helps improve patient outcomes by providing additional time for supportive care while reducing the source of inflammation and potentially preventing further damage by reducing virus in the bloodstream.